Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds

Revenue Grows But Profits Take A Hit At Bangladeshi Generics Firm

Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.

Beximco logo
The war in Ukraine, supply chain disruptions and currency depreciation could spell a bad time for Beximco • Source: Shutterstock

Beximco managing director Nazmul Hassan has warned shareholders that headwinds including the war in Ukraine, supply chain disruptions and record depreciation of local currency are set to have an impact on the Bangladeshi company from Q1 onward, following the unveiling of its results for the 12-month period ended 30 June 2022.

“We remain committed to expanding our businesses, seeking operational efficiencies and delivering on our strategy to maximize the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

 
• By 

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By 

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.